BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 19862816)

  • 1. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
    Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
    Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?
    Baur A; Stäbler A; Nagel D; Lamerz R; Bartl R; Hiller E; Wendtner C; Bachner F; Reiser M
    Cancer; 2002 Sep; 95(6):1334-45. PubMed ID: 12216103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
    Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
    Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of MRI for the diagnosis and prognosis of multiple myeloma.
    Baur-Melnyk A; Buhmann S; Dürr HR; Reiser M
    Eur J Radiol; 2005 Jul; 55(1):56-63. PubMed ID: 15950101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
    Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of multiple myeloma: a report of 182 cases].
    Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
    Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
    Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
    Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
    Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor diameter and volume assessed by magnetic resonance imaging in the prediction of outcome for invasive cervical cancer.
    Wagenaar HC; Trimbos JB; Postema S; Anastasopoulou A; van der Geest RJ; Reiber JH; Kenter GG; Peters AA; Pattynama PM
    Gynecol Oncol; 2001 Sep; 82(3):474-82. PubMed ID: 11520143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging of pelvic and femoral bones for detection of bone marrow infiltration in patients with non-Hodgkins lymphoma.
    Al-Mulhim FA
    Saudi Med J; 2005 Jan; 26(1):31-6. PubMed ID: 15756349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.
    Corso A; Arcaini L; Mangiacavalli S; Astori C; Orlandi E; Lorenzi A; Passamonti F; Klersy C; Pascutto C; Canevari-Sciorati A; Lazzarino M
    Haematologica; 2001 Apr; 86(4):394-8. PubMed ID: 11325645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
    Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
    Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.